RXST
RxSight, Inc. NASDAQ Listed Jul 30, 2021$5.80
Mkt Cap $239.3M
52w Low $5.30
4.4% of range
52w High $16.74
50d MA $7.16
200d MA $8.77
P/E (TTM)
-7.8x
EV/EBITDA
-10.6x
P/B
1.1x
Debt/Equity
0.0x
ROE
-14.1%
P/FCF
-22.2x
RSI (14)
—
ATR (14)
—
Beta
1.21
50d MA
$7.16
200d MA
$8.77
Avg Volume
876.2K
RxSight, Inc., a medical technology company, engages in the research and development, manufacture, and sale of light adjustable intraocular lenses (LAL) used in cataract surgery in the United States and internationally. It offers RxSight system that enables doctors to customize and enhance the visual acuity for patients after cataract surgery. The company's RxSight system includes RxSight light delivery device, an office-based light treatment device that delivers UV light in a programmed pattern to modify the LAL based on the visual correction needed to achieve desired vision after cataract surgery. It primarily serves cataract doctors. The company was formerly known as Calhoun Vision, Inc. and changed its name to RxSight, Inc. in February 2017. RxSight, Inc. was incorporated in 1997 and is headquartered in Aliso Viejo, California.
100 Columbia · Aliso Viejo, CA 92656 · US
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| May 6, 2026 | AMC | -0.12 | -0.38 | -216.7% | 6.78 | -8.4% | -14.5% | — | — | — | — | — |
| Feb 25, 2026 | AMC | -0.33 | -0.22 | +34.3% | 8.81 | -13.6% | -10.1% | -5.6% | +1.7% | +0.1% | +4.1% | — |
| Nov 5, 2025 | AMC | -0.19 | -0.04 | +78.9% | 8.34 | +18.7% | +3.2% | +8.8% | +7.9% | +1.2% | -2.2% | — |
| Aug 7, 2025 | AMC | -0.10 | -0.08 | +20.0% | 7.79 | -4.4% | -7.7% | -7.5% | +10.5% | +13.1% | -1.1% | — |
| May 7, 2025 | AMC | -0.22 | -0.20 | +7.7% | 14.90 | +3.4% | -11.2% | -1.3% | +5.3% | -4.0% | +0.3% | — |
| Feb 25, 2025 | AMC | 0.10 | 0.03 | -70.0% | 29.21 | -6.1% | -0.8% | -2.6% | +0.5% | -5.0% | -0.3% | — |
| Nov 7, 2024 | AMC | -0.25 | -0.16 | +36.0% | 50.85 | -7.5% | -5.6% | -3.5% | -1.9% | -1.8% | -1.1% | — |
| Aug 5, 2024 | AMC | -0.22 | -0.16 | +27.3% | 40.78 | +23.6% | +17.3% | -3.4% | +6.7% | +2.8% | +2.8% | — |
| May 6, 2024 | AMC | -0.17 | -0.12 | +29.4% | 62.84 | +5.9% | -1.0% | -2.5% | +1.3% | -3.4% | -0.9% | — |
| Feb 28, 2024 | AMC | -0.36 | -0.26 | +27.8% | 56.39 | +2.4% | -3.2% | +2.1% | +0.7% | -2.9% | -1.4% | — |
| Nov 9, 2023 | AMC | -0.42 | -0.35 | +16.7% | 23.80 | -1.2% | +6.2% | +2.4% | +5.1% | +1.0% | +2.4% | — |
| Aug 7, 2023 | AMC | -0.47 | -0.40 | +14.9% | 28.84 | +11.0% | +2.7% | -6.8% | +1.2% | +0.8% | +4.9% | — |
| May 9, 2023 | AMC | -0.52 | -0.42 | +19.2% | 19.25 | +3.9% | +9.9% | +3.9% | +4.5% | -1.4% | +3.8% | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mar 9 | Stifel | Maintains | Hold → Hold | — | $7.69 | $7.36 | -4.3% | -1.6% | -0.8% | -1.6% | +3.4% | -4.1% |
| Feb 26 | UBS | Maintains | Neutral → Neutral | — | $8.81 | $7.61 | -13.6% | -10.1% | -5.6% | +1.7% | +0.1% | +4.1% |
| Feb 26 | Piper Sandler | Maintains | Neutral → Neutral | — | $8.81 | $7.61 | -13.6% | -10.1% | -5.6% | +1.7% | +0.1% | +4.1% |
| Feb 26 | Needham | Maintains | Buy → Buy | — | $8.81 | $7.61 | -13.6% | -10.1% | -5.6% | +1.7% | +0.1% | +4.1% |
| Jan 20 | Piper Sandler | Maintains | Neutral → Neutral | — | $9.81 | $9.79 | -0.2% | -1.5% | +3.0% | -0.9% | -3.5% | +0.4% |
| Dec 2 | Morgan Stanley | Maintains | Equal Weight → Equal Weight | — | $11.65 | $11.52 | -1.1% | +0.9% | +0.9% | +5.3% | +1.1% | -0.6% |
| Nov 6 | Wells Fargo | Maintains | Equal Weight → Equal Weight | — | $8.34 | $9.90 | +18.7% | +3.2% | +8.8% | +7.9% | +1.2% | -2.2% |
| Nov 6 | Needham | Maintains | Buy → Buy | — | $8.34 | $9.90 | +18.7% | +3.2% | +8.8% | +7.9% | +1.2% | -2.2% |
| Nov 6 | JP Morgan | Maintains | Underweight → Underweight | — | $8.34 | $9.90 | +18.7% | +3.2% | +8.8% | +7.9% | +1.2% | -2.2% |
| Aug 8 | UBS | Maintains | Neutral → Neutral | — | $7.79 | $7.45 | -4.4% | -7.7% | -7.5% | +10.5% | +13.1% | -1.1% |
| Aug 8 | Stifel | Maintains | Hold → Hold | — | $7.79 | $7.45 | -4.4% | -7.7% | -7.5% | +10.5% | +13.1% | -1.1% |
| Aug 8 | Needham | Maintains | Buy → Buy | — | $7.79 | $7.45 | -4.4% | -7.7% | -7.5% | +10.5% | +13.1% | -1.1% |
| Jul 15 | Morgan Stanley | Downgrade | Overweight → Equal Weight | — | $7.74 | $7.62 | -1.6% | -3.7% | -2.3% | +1.4% | -0.4% | +0.0% |
| Jul 10 | Jefferies | Downgrade | Buy → Hold | — | $7.95 | $7.97 | +0.3% | +6.4% | -5.4% | -3.2% | -3.7% | -2.3% |
| Jul 9 | Wells Fargo | Downgrade | Overweight → Equal Weight | — | $12.79 | $6.44 | -49.6% | -37.8% | +6.4% | -5.4% | -3.3% | -3.7% |
| Jul 9 | BofA Securities | Maintains | Underperform → Underperform | — | $12.79 | $6.44 | -49.6% | -37.8% | +6.4% | -5.4% | -3.3% | -3.7% |
| Jul 9 | Stifel | Maintains | Hold → Hold | — | $12.79 | $6.44 | -49.6% | -37.8% | +6.4% | -5.4% | -3.3% | -3.7% |
| Jul 9 | Piper Sandler | Maintains | Neutral → Neutral | — | $12.79 | $6.44 | -49.6% | -37.8% | +6.4% | -5.4% | -3.3% | -3.7% |
| Jul 9 | Needham | Maintains | Buy → Buy | — | $12.79 | $6.44 | -49.6% | -37.8% | +6.4% | -5.4% | -3.3% | -3.7% |
| Jul 9 | BTIG | Downgrade | Buy → Neutral | — | $12.79 | $6.44 | -49.6% | -37.8% | +6.4% | -5.4% | -3.3% | -3.7% |
| May 19 | Wells Fargo | Upgrade | Equal Weight → Overweight | — | $14.19 | $15.39 | +8.5% | +15.0% | +1.8% | -3.7% | -0.7% | -1.3% |
| Apr 9 | UBS | Downgrade | Buy → Neutral | — | $14.99 | $14.36 | -4.2% | +3.5% | -8.5% | -0.8% | +2.4% | +1.4% |
| Apr 8 | Needham | Maintains | Buy → Buy | — | $16.61 | $17.29 | +4.1% | -9.8% | +3.5% | -8.5% | -0.8% | +2.4% |
| Apr 7 | Wells Fargo | Maintains | Equal Weight → Equal Weight | — | $16.26 | $15.42 | -5.2% | +2.2% | -9.8% | +3.5% | -8.5% | -0.8% |
| Apr 4 | JP Morgan | Downgrade | Overweight → Underweight | — | $16.21 | $15.17 | -6.4% | +0.3% | +2.2% | -9.8% | +3.5% | -8.5% |
| Apr 3 | Wells Fargo | Maintains | Equal Weight → Equal Weight | — | $26.12 | $16.00 | -38.7% | -37.9% | +0.3% | +2.2% | -9.8% | +3.5% |
| Apr 3 | Needham | Maintains | Buy → Buy | — | $26.12 | $16.00 | -38.7% | -37.9% | +0.3% | +2.2% | -9.8% | +3.5% |
| Mar 21 | BofA Securities | Maintains | Buy → Buy | — | $24.90 | $24.35 | -2.2% | -0.2% | +0.3% | -0.9% | -1.3% | +9.4% |
| Mar 19 | Stifel | Maintains | Hold → Hold | — | $25.73 | $25.41 | -1.2% | -3.4% | +0.2% | -0.2% | +0.3% | -0.9% |
| Feb 26 | Wells Fargo | Maintains | Equal Weight → Equal Weight | — | $29.21 | $27.44 | -6.1% | -0.8% | -2.6% | +0.5% | -5.0% | -0.3% |
| Feb 26 | Stifel | Maintains | Hold → Hold | — | $29.21 | $27.44 | -6.1% | -0.8% | -2.6% | +0.5% | -5.0% | -0.3% |
| Feb 26 | Needham | Maintains | Buy → Buy | — | $29.21 | $27.44 | -6.1% | -0.8% | -2.6% | +0.5% | -5.0% | -0.3% |
| Feb 26 | JP Morgan | Maintains | Overweight → Overweight | — | $29.21 | $27.44 | -6.1% | -0.8% | -2.6% | +0.5% | -5.0% | -0.3% |
| Jan 13 | Stifel | Maintains | Hold → Hold | — | $33.43 | $32.66 | -2.3% | -8.1% | -2.1% | +4.1% | -0.4% | -2.5% |
| Jan 13 | Wells Fargo | Maintains | Equal Weight → Equal Weight | — | $33.43 | $32.66 | -2.3% | -8.1% | -2.1% | +4.1% | -0.4% | -2.5% |
| Jan 13 | Needham | Maintains | Buy → Buy | — | $33.43 | $32.66 | -2.3% | -8.1% | -2.1% | +4.1% | -0.4% | -2.5% |
| Dec 20 | Stifel | Downgrade | Buy → Hold | — | $38.19 | $35.41 | -7.3% | -11.9% | +2.8% | -0.3% | +1.7% | -2.4% |
| Dec 17 | Needham | Maintains | Buy → Buy | — | $38.49 | $38.30 | -0.5% | -1.2% | -2.2% | +2.7% | -11.9% | +2.8% |
| Dec 11 | Wells Fargo | Downgrade | Overweight → Equal Weight | — | $39.17 | $37.51 | -4.2% | -4.1% | -4.5% | +3.9% | +3.2% | -1.2% |
| Sep 13 | Needham | Maintains | Buy → Buy | — | $54.54 | $54.83 | +0.5% | +0.8% | +1.1% | +1.1% | -3.5% | -1.1% |
| Aug 20 | Needham | Maintains | Buy → Buy | — | $52.83 | $53.89 | +2.0% | +1.8% | -0.2% | +1.2% | +3.9% | -1.0% |
| Aug 6 | Needham | Maintains | Buy → Buy | — | $40.78 | $50.41 | +23.6% | +17.3% | -3.4% | +6.7% | +2.8% | +2.8% |
| Aug 6 | Stifel | Maintains | Buy → Buy | — | $40.78 | $50.41 | +23.6% | +17.3% | -3.4% | +6.7% | +2.8% | +2.8% |
| Aug 6 | Wells Fargo | Maintains | Overweight → Overweight | — | $40.78 | $50.41 | +23.6% | +17.3% | -3.4% | +6.7% | +2.8% | +2.8% |
| Aug 6 | Oppenheimer | Maintains | Outperform → Outperform | — | $40.78 | $50.41 | +23.6% | +17.3% | -3.4% | +6.7% | +2.8% | +2.8% |
| Jul 15 | BTIG | Maintains | Buy → Buy | — | $47.72 | $48.95 | +2.6% | +1.9% | +1.6% | -4.5% | -2.5% | +1.6% |
| Jul 10 | Stifel | Maintains | Buy → Buy | — | $56.99 | $55.89 | -1.9% | -10.3% | -2.6% | -4.1% | +1.9% | +1.6% |
| May 7 | Needham | Maintains | Buy → Buy | — | $62.84 | $66.54 | +5.9% | -1.0% | -2.5% | +1.3% | -3.4% | -0.9% |
| May 7 | BTIG | Maintains | Buy → Buy | — | $62.84 | $66.54 | +5.9% | -1.0% | -2.5% | +1.3% | -3.4% | -0.9% |
| May 7 | Wells Fargo | Maintains | Overweight → Overweight | — | $62.84 | $66.54 | +5.9% | -1.0% | -2.5% | +1.3% | -3.4% | -0.9% |
No insider trades available.
8-K
Unknown — 8-K Filing
A four-year vesting schedule for executive options incentivizes long-term retention at RXST, reducing near-term dilution while aligning management's interests with sustained stock performance.
Mar 19
8-K
RxSight, Inc. -- 8-K Filing
RxSight's 2025 LAL (light-adjustable lens) revenue grew strongly year-over-year, indicating successful market adoption and physician acceptance of their differentiated ophthalmic technology.
Feb 25
Data updated apr 26, 2026 11:50pm
· Source: massive.com